Input Symbol (pharmaceutics and related company): |
Show Other Options
US Clinical Trail Options | |||
Field(s): | Type(s): | Status(es): | Phase(s): |
Default Sorting: | |||
US FDA Submission Options | |||
Field(s): | Class(s): | Type(s): | |
US Drug Marketing Status Options | |||
Field(s): | |||
EU Drug Marketing Status Options | |||
Field(s): | |||
CA Drug Marketing Status Options | |||
Field(s): | |||
General Options | |||
Historical Years: | Display Records Number: | ||
Plot Options & Overlay | |||
Price Chart: | Technical Indicators: | Clinical Trails: | FDA Submissions: |
US Marketing: | EU Marketing: | CA Marketing: |
Full Name:Teva Pharmaceutical Industries Limited | Industry:pharmaceuticals | CIK:818686 | Fiscal Year End:12-31 | State/Country:ISRAEL |
Check Quant Chart for other overlays (E.g. SEC filings, Insider tradings) to get more accurate projection of price movement
Show Plot Instructions Expand All
Instructions
US clinical trial status
Size of symbol reflects the phase of clinical trial. E.g. Phase 3 trial has the largest size.
Shape definition
▲ Up-triangle: study first submitted.
◼ Square: study completion(actual/anticipated).
⬤ Circle: result first posted.
Color definition
▶ Green: study is ongoing.
▶ Blue: recruitment completed.
▶ Red: study aborted/terminated/withdrawn.
▶ Pink: study in abnormal state.
US FDA submission
Size of symbol reflects the type of submission. E.g. Type 1 drug has the largest size.
◆: Approved.
◆: Tentative Approval.
Drug marketing & current status
Circle bubble denotes new drug marketing. Size is determined by drug type and market(i.e. population) size. E.g. Type 1 drug marketed in US has the largest size. Drug marketed in CA has the smallest size due to small population size.
Color definition
⬤ Blue circle: drug marketed (EU,CA), FDA submission approved (US).
⬤ Cyan circle: drug approved (CA), tentative approval (US), received positive opinion (EU)
⬤ Red circle: drug marketed/approved on the corresponding day but was later withdrawn, discontinued, cancelled, or received negative opinion.
Drug marketing status change
Square bubble denotes marketing status change. Size is determined by drug type and market(i.e. population) size.
Color definition
◼ Blue square: change from other status to marketed.
◼ Cyan square: change from other status to tentative status.
◼ Red square: change from other status to abnormal or withdrawn status.
Clinical Trials Summary Statistics
Year | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
ALL | 4 ⬤ | 193 ⬤ | 4 | |||
2024 | 4 ⬤ | |||||
2023 | ||||||
2022 |
Year | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
ALL | 8 | 4 ⬤ | ||||
2024 | ||||||
2023 | ||||||
2022 |
Year | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
ALL | 2 ⬤ | 41 | 8 | 6 | ||
2024 | ||||||
2023 | ||||||
2022 | 2 ⬤ |
Year | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
ALL | 3 ⬤ | |||||
2024 | ||||||
2023 | ||||||
2022 |
Year | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
ALL | 3 ⬤ | 2 ⬤ | 82 ⬤ | 1 | 15 ⬤ | 1 |
2024 | ||||||
2023 | 1 ⬤ | 1 ⬤ | ||||
2022 | 1 ⬤ | 2 ⬤ |
Year | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
ALL | 15 | 5 | 1 | |||
2024 | ||||||
2023 | ||||||
2022 |
Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 |
---|---|---|---|---|---|---|
ALL | 4 ⬤ | 2 ⬤ | 3 ⬤ | |||
2024 | 4 ⬤ | |||||
2023 | 1 ⬤ | |||||
2022 | 2 ⬤ |
Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 |
---|---|---|---|---|---|---|
ALL | 2 ⬤ | |||||
2024 | ||||||
2023 | 1 ⬤ | |||||
2022 | 1 ⬤ |
Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 |
---|---|---|---|---|---|---|
ALL | 193 ⬤ | 8 | 41 | 3 ⬤ | 82 ⬤ | 15 |
2024 | ||||||
2023 | ||||||
2022 | 2 ⬤ |
Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 |
---|---|---|---|---|---|---|
ALL | 1 | |||||
2024 | ||||||
2023 | ||||||
2022 |
Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 |
---|---|---|---|---|---|---|
ALL | 4 | 4 ⬤ | 8 | 15 ⬤ | 5 | |
2024 | ||||||
2023 | ||||||
2022 |
Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 |
---|---|---|---|---|---|---|
ALL | 6 | 1 | 1 | |||
2024 | ||||||
2023 | ||||||
2022 |
Phase | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
Phase 1 | 4 ⬤ | 193 ⬤ | 4 | |||
Phase 1|Phase 2 | 8 | 4 ⬤ | ||||
Phase 2 | 2 ⬤ | 41 | 8 | 6 | ||
Phase 2|Phase 3 | 3 ⬤ | |||||
Phase 3 | 3 ⬤ | 2 ⬤ | 82 ⬤ | 1 | 15 ⬤ | 1 |
Phase 4 | 15 | 5 | 1 |
Phase | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
Phase 1 | 4 ⬤ | |||||
Phase 1|Phase 2 | ||||||
Phase 2 | ||||||
Phase 2|Phase 3 | ||||||
Phase 3 | ||||||
Phase 4 |
Phase | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
Phase 1 | ||||||
Phase 1|Phase 2 | ||||||
Phase 2 | ||||||
Phase 2|Phase 3 | ||||||
Phase 3 | 1 ⬤ | 1 ⬤ | ||||
Phase 4 |
Phase | Recruiting | Active, Not Recruiting | Completed | Unknown Status | Terminated | Withdrawn |
---|---|---|---|---|---|---|
Phase 1 | ||||||
Phase 1|Phase 2 | ||||||
Phase 2 | 2 ⬤ | |||||
Phase 2|Phase 3 | ||||||
Phase 3 | 1 ⬤ | 2 ⬤ | ||||
Phase 4 |
Note: "Year" represents clinical trail start year determined by study first submit date.
Three grouping strategies present the same statistical data from different angles, choose any one you are comfortable with.
⬤ at least one study with latest update posted within 7 days.
⬤ at least one study with latest update posted within 30 days.
⬤ at least one study with latest update posted within 90 days.
Clinical Trials Records
Sponsor | Overall Status | Phase | Brief Title | Disease Condition | Intervention Name | Study First Submit Date | Last Update Post Date | Results First Post Date | Completion Date | Completion Date Type | Enrollment Count |
---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting | Phase 3 | A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Asthma | TEV-56248|Albuterol sulfate | 2023-09-18 | 2024-04-17 | 2026-07-17 | Anticipated | 2196 | |
Teva Branded Pharmaceutical Products R&D, Inc. | Active, not recruiting | Phase 3 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia | Schizophrenia | TV-44749 - Dose level 1|TV-44749 - Dose level 2|TV-44749 - Dose level 3|Placebo | 2023-01-12 | 2024-04-22 | 2025-01-13 | Anticipated | 675 | |
Teva Pharmaceuticals USA | Completed | Phase 3 | Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy | Dyspareunia | Estradiol|Imvexxy|Placebo | 2022-11-07 | 2024-04-12 | 2024-03-15 | Actual | 1050 | |
Teva Pharmaceuticals USA | Completed | Phase 3 | Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris | Acne Vulgaris | Trifarotene 0.005 % Topical Cream|AKLIEF®|Placebo | 2022-09-19 | 2023-08-24 | 2023-05-09 | Actual | 807 | |
Teva Branded Pharmaceutical Products R&D, Inc. | Active, not recruiting | Phase 3 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine | Migraine | Fremanezumab|Placebo | 2022-07-11 | 2024-02-08 | 2024-07-03 | Anticipated | 365 |
Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "phase 3" (case insensitive, with double quote) to show Phase 3 trials.
⬤ latest update posted within 7 days.
⬤ latest update posted within 30 days.
⬤ latest update posted within 90 days.
US FDA Submission Summary Statistics*
Year | TYPE 1 | TYPE 2 | TYPE 2/4 | TYPE 3 | TYPE 4 | TYPE 5 | TYPE 9 | N/A | UNKNOWN |
---|---|---|---|---|---|---|---|---|---|
ALL | 17 | 3 | 1 | 29 | 3 | 16 | 1 | 14 | 148 |
2024 | |||||||||
2023 | 2 | 12 | |||||||
2022 | 1 | 1 | 30 |
Note: "Year" determined by submission status date.
* Original submissions only. Supplementary records not counted.
⬤ at least one submission within 7 days.
⬤ at least one submission within 30 days.
⬤ at least one submission within 90 days.
US FDA Submission Records
Sponsor | Application Type | Drug Name | Active Ingredient | Submission Code | Submission Type | Submission Status | Status Date | Application Number |
---|---|---|---|---|---|---|---|---|
Teva Pharms Inc | ANDA | Orig 1 | Tentative | 2024-03-08 | 216931 | |||
Teva Pharms Usa Inc | ANDA | Orig 1 | Tentative | 2024-02-01 | 209813 | |||
Teva Pharms Usa Inc | ANDA | Cyclosporine | Cyclosporine | Orig 1 | Approval | 2023-12-14 | 203880 | |
Teva Pharms Usa Inc | ANDA | Octreotide Acetate | Octreotide Acetate | Orig 1 | Approval | 2023-12-05 | 210317 | |
Teva Pharms Usa Inc | ANDA | Risperidone | Risperidone | Orig 1 | Approval | 2023-12-05 | 214068 | |
Teva Pharms Usa | ANDA | Teriparatide | Teriparatide | Orig 1 | Approval | 2023-11-16 | 208569 | |
Teva Pharms Inc | ANDA | Unknown | Orig | Tentative Approval | 2023-10-26 | 217825 | ||
Teva Pharms Inc | ANDA | Pazopanib | Pazopanib | Unknown | Orig | Approval | 2023-10-19 | 217517 |
Teva Pharms Usa Inc | ANDA | Unknown | Orig | Tentative Approval | 2023-08-29 | 217635 | ||
Teva Pharms | ANDA | Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | Unknown | Orig | Approval | 2023-08-25 | 215415 |
Teva Pharms Usa Inc | ANDA | Plerixafor | Plerixafor | Unknown | Orig | Approval | 2023-07-24 | 205197 |
Teva Pharms Usa Inc | ANDA | Naltrexone | Naltrexone | Unknown | Orig | Approval | 2023-07-06 | 213195 |
Teva Pharms Inc | ANDA | Unknown | Orig | Tentative Approval | 2023-05-23 | 216770 | ||
Teva Pharms Inc | NDA | Paclitaxel | Paclitaxel | Type 5 | Orig | Approval | 2023-05-11 | 216338 |
Teva | NDA | Uzedy | Risperidone | Type 5 | Orig | Approval | 2023-04-28 | 213586 |
Teva Pharms | ANDA | Doxepin Hydrochloride | Doxepin Hydrochloride | Unknown | Orig | Approval | 2023-02-17 | 215408 |
Teva | NDA | Austedo Xr | Deutetrabenazine | Unknown | Orig | Approval | 2023-02-17 | 216354 |
Teva Pharms Usa | ANDA | Methylphenidate Hydrochloride | Methylphenidate Hydrochloride | Unknown | Orig | Tentative Approval | 2023-02-07 | 214202 |
Teva Pharms Usa | ANDA | Abiraterone Acetate | Abiraterone Acetate | Unknown | Orig | Approval | 2023-01-26 | 210726 |
Teva Pharms Usa Inc | ANDA | Aspirin; Omeprazole | Aspirin;Omeprazole | Unknown | Orig | Tentative Approval | 2023-01-20 | 209791 |
Teva Pharms Usa Inc | ANDA | Tasimelteon | Tasimelteon | Unknown | Orig | Approval | 2022-12-12 | 211601 |
Teva Pharms Inc | ANDA | Valbenazine Tosylate | Valbenazine Tosylate | Unknown | Orig | Tentative Approval | 2022-11-25 | 215984 |
Teva Pharms Usa | ANDA | Penciclovir | Penciclovir | Unknown | Orig | Approval | 2022-11-09 | 212710 |
Teva Pharms Usa Inc | ANDA | Oxymetazoline | Oxymetazoline | Unknown | Orig | Tentative Approval | 2022-10-28 | 211812 |
Teva Pharms Inc | ANDA | Cabozantinib | Cabozantinib | Unknown | Orig | Tentative Approval | 2022-10-27 | 215942 |
Teva Pharms Inc | ANDA | Alyq | Tadalafil | Unknown | Orig | Approval | 2022-10-12 | 216932 |
Teva Pharms Inc | ANDA | Theophylline | Theophylline | Unknown | Orig | Approval | 2022-10-12 | 216961 |
Watson Labs Teva | ANDA | Brimonidine Tartrate And Timolol Maleate | Brimonidine Tartrate; Timolol Maleate | N/A | Orig | Approval | 2022-10-04 | 201949 |
Teva Pharms | NDA | Alvaiz | Eltrombopag Choline | Type 2 | Orig | Tentative Approval | 2022-10-03 | 216774 |
Teva Pharms Usa | ANDA | Deferasirox | Deferasirox | Unknown | Orig | Approval | 2022-09-23 | 207124 |
Teva Pharms Usa Inc | ANDA | Apremilast | Apremilast | Unknown | Orig | Approval | 2022-08-18 | 211897 |
Teva Pharms Inc | ANDA | Cetrorelix Acetate | Cetrorelix Acetate | Unknown | Orig | Approval | 2022-08-12 | 215737 |
Teva Pharms Usa Inc | ANDA | Brexpiprazole | Brexpiprazole | Unknown | Orig | Approval | 2022-08-11 | 213692 |
Teva Pharms Usa Inc | ANDA | Dapagliflozin;Metformin Hydrochloride | Dapagliflozin;Metformin Hydrochloride | Unknown | Orig | Tentative Approval | 2022-08-03 | 211583 |
Teva Pharms Usa Inc | ANDA | Perampanel | Perampanel | Unknown | Orig | Tentative Approval | 2022-07-01 | 209801 |
Teva Pharms Usa Inc | ANDA | Dasatinib | Dasatinib | Unknown | Orig | Tentative Approval | 2022-07-01 | 211094 |
Teva Pharms Usa | ANDA | Abiraterone Acetate | Abiraterone Acetate | Unknown | Orig | Approval | 2022-06-24 | 212206 |
Teva Pharms Usa | ANDA | Canagliflozin | Canagliflozin | Unknown | Orig | Tentative Approval | 2022-06-14 | 210451 |
Watson Labs Teva | ANDA | Levothyroxine Sodium | Levothyroxine Sodium | Unknown | Orig | Approval | 2022-05-10 | 207588 |
Teva Pharms Usa | ANDA | Mesalamine | Mesalamine | Unknown | Orig | Approval | 2022-05-06 | 209970 |
Teva Pharms Usa | ANDA | Pomalidomide | Pomalidomide | Unknown | Orig | Approval | 2022-05-04 | 209956 |
Teva Pharms Usa | ANDA | Zileuton | Zileuton | Unknown | Orig | Approval | 2022-05-03 | 211043 |
Teva Pharms Usa | ANDA | Bortezomib | Bortezomib | Unknown | Orig | Approval | 2022-05-02 | 205857 |
Teva Pharms Usa | ANDA | Dofetilide | Dofetilide | Unknown | Orig | Approval | 2022-04-15 | 210018 |
Teva Pharms Usa Inc | ANDA | Riociguat | Riociguat | Unknown | Orig | Tentative Approval | 2022-03-30 | 211044 |
Teva Pharms Usa | ANDA | Ivermectin | Ivermectin | Unknown | Orig | Approval | 2022-03-21 | 212485 |
Teva Pharms | ANDA | Unknown | Orig | Tentative Approval | 2022-02-23 | 216076 | ||
Teva Pharms Usa | ANDA | Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate | Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate | Unknown | Orig | Approval | 2022-01-31 | 210876 |
Teva Pharms Usa Inc | ANDA | Sofosbuvir | Sofosbuvir | Unknown | Orig | Approval | 2022-01-27 | 211353 |
Teva Pharms Usa | ANDA | Pirfenidone | Pirfenidone | Unknown | Orig | Approval | 2022-01-25 | 212759 |
Teva Pharms Usa | ANDA | Mycophenolate Mofetil | Mycophenolate Mofetil | Unknown | Orig | Approval | 2022-01-25 | 211272 |
Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "NDA" (case insensitive) to show records with "NDA" (New Drug Applications) tag.
⬤ submission status date within 7 days.
⬤ submission status date within 30 days.
⬤ submission status date within 90 days.
Category | Sponsor | Marketing Date | Current Marketing Status | Drug Name | Active Ingredient | Submission Status Date | Submission Code | Submission Status | Marketing Status Change Date |
---|---|---|---|---|---|---|---|---|---|
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | 2023-10-26 | Unknown | Tentative Approval | 2023-11-30 | |||
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | 2023-10-26 | Unknown | Tentative Approval | 2023-11-30 | |||
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | 2023-10-26 | Unknown | Tentative Approval | 2023-11-30 | |||
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | 2023-10-26 | Unknown | Tentative Approval | 2023-11-30 | |||
Human Non-Bioproduct | Teva Pharms Inc | 2023-10-19 | Prescription | Pazopanib | Pazopanib | 2023-10-19 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Usa Inc | None (Tentative Approval) | 2023-08-29 | Unknown | Tentative Approval | 2023-11-30 | |||
Human Non-Bioproduct | Teva Pharms | 2023-08-25 | Prescription | Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 2023-08-25 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms | 2023-08-25 | Prescription | Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 2023-08-25 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms | 2023-08-25 | Prescription | Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 2023-08-25 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms | 2023-08-25 | Prescription | Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 2023-08-25 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms | 2023-08-25 | Prescription | Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 2023-08-25 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms | 2023-08-25 | Prescription | Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 2023-08-25 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Usa Inc | 2023-07-24 | Prescription | Plerixafor | Plerixafor | 2023-07-24 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Usa Inc | 2023-07-06 | Prescription | Naltrexone | Naltrexone | 2023-07-06 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | 2023-05-23 | Unknown | Tentative Approval | 2023-11-30 | |||
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | 2023-05-23 | Unknown | Tentative Approval | 2023-11-30 | |||
Human Non-Bioproduct | Teva Pharms Inc | 2023-05-11 | Prescription | Paclitaxel | Paclitaxel | 2023-05-11 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-04-28 | Prescription | Uzedy | Risperidone | 2023-04-28 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-04-28 | Prescription | Uzedy | Risperidone | 2023-04-28 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-04-28 | Prescription | Uzedy | Risperidone | 2023-04-28 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-04-28 | Prescription | Uzedy | Risperidone | 2023-04-28 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-04-28 | Prescription | Uzedy | Risperidone | 2023-04-28 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-04-28 | Prescription | Uzedy | Risperidone | 2023-04-28 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-04-28 | Prescription | Uzedy | Risperidone | 2023-04-28 | Type 5 | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-02-17 | Prescription | Austedo Xr | Deutetrabenazine | 2023-02-17 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-02-17 | Prescription | Austedo Xr | Deutetrabenazine | 2023-02-17 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva | 2023-02-17 | Prescription | Austedo Xr | Deutetrabenazine | 2023-02-17 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms | 2023-02-17 | Prescription | Doxepin Hydrochloride | Doxepin Hydrochloride | 2023-02-17 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Usa | None (Tentative Approval) | Methylphenidate Hydrochloride | Methylphenidate Hydrochloride | 2023-02-07 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Usa | None (Tentative Approval) | Methylphenidate Hydrochloride | Methylphenidate Hydrochloride | 2023-02-07 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Usa | None (Tentative Approval) | Methylphenidate Hydrochloride | Methylphenidate Hydrochloride | 2023-02-07 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Usa | 2023-01-26 | Prescription | Abiraterone Acetate | Abiraterone Acetate | 2023-01-26 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Usa Inc | None (Tentative Approval) | Aspirin; Omeprazole | Aspirin;Omeprazole | 2023-01-20 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Usa Inc | None (Tentative Approval) | Aspirin; Omeprazole | Aspirin;Omeprazole | 2023-01-20 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Usa Inc | 2022-12-12 | Prescription | Tasimelteon | Tasimelteon | 2022-12-12 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | Valbenazine Tosylate | Valbenazine Tosylate | 2022-11-25 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Inc | None (Tentative Approval) | Valbenazine Tosylate | Valbenazine Tosylate | 2022-11-25 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Usa | 2022-11-09 | Prescription | Penciclovir | Penciclovir | 2022-11-09 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Usa Inc | None (Tentative Approval) | Oxymetazoline | Oxymetazoline | 2022-10-28 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Inc | Prescription | Cabozantinib | Cabozantinib | 2022-10-27 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Inc | Prescription | Cabozantinib | Cabozantinib | 2022-10-27 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Inc | Prescription | Cabozantinib | Cabozantinib | 2022-10-27 | Unknown | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Inc | 2022-10-12 | Prescription | Theophylline | Theophylline | 2022-10-12 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Inc | 2022-10-12 | Prescription | Theophylline | Theophylline | 2022-10-12 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms Inc | 2022-10-12 | Prescription | Alyq | Tadalafil | 2022-10-12 | Unknown | Approval | 2023-11-30 |
Human Non-Bioproduct | Watson Labs Teva | 2022-10-04 | Prescription | Brimonidine Tartrate And Timolol Maleate | Brimonidine Tartrate; Timolol Maleate | 2022-10-04 | N/A | Approval | 2023-11-30 |
Human Non-Bioproduct | Teva Pharms | None (Tentative Approval) | Alvaiz | Eltrombopag Choline | 2022-10-03 | Type 2 | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms | None (Tentative Approval) | Alvaiz | Eltrombopag Choline | 2022-10-03 | Type 2 | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms | None (Tentative Approval) | Alvaiz | Eltrombopag Choline | 2022-10-03 | Type 2 | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms | None (Tentative Approval) | Alvaiz | Eltrombopag Choline | 2022-10-03 | Type 2 | Tentative Approval | 2023-11-30 | |
Human Non-Bioproduct | Teva Pharms Usa | 2022-09-23 | Discontinued | Deferasirox | Deferasirox | 2022-09-23 | Unknown | Approval | 2023-11-30 |
Note: This table contains human and animal drugs regulated by US FDA, and biological products regulated by CBER (Center for Biologics Evaluation and Research).
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "discontinued" (case insensitive) to show discontinued drug products.
For human non-bioproduct, marketing date was set to submission approval date.
Possible marketing statuses: Marketed, Prescription, Over-the-counter, Discontinued, None (Tentative Approval).
⬤ any of (marketing/submission/status change) within 7 days.
⬤ any of (marketing/submission/status change) within 30 days.
⬤ any of (marketing/submission/status change) within 90 days.
Category | Sponsor | Authorization Date | Current Marketing Status | Latest Status Update | Drug Name | Active Ingredient | Withdraw Date | Opinion Date | Summary of Opinion |
---|---|---|---|---|---|---|---|---|---|
Human | Teva Gmb H | 2022-12-12 | Authorised | 2022-12-22 | Dimethyl fumarate Teva | Dimethyl Fumarate | |||
Human | Teva B.V. | 2012-03-26 | Withdrawn | 2023-05-04 | Pioglitazone Teva | Pioglitazone Hydrochloride | |||
Human | Teva Pharma B.V. | 2012-03-26 | Withdrawn | 2022-08-30 | Pioglitazone Teva Pharma | Pioglitazone Hydrochloride | |||
Human | Teva Pharma B.V. | 2011-02-28 | Withdrawn | 2023-03-21 | Lamivudine/Zidovudine Teva | Lamivudine, Zidovudine | |||
Human | Teva B.V. | 2009-11-30 | Withdrawn | 2023-03-21 | Nevirapine Teva | Nevirapine |
Note: This table contains human and animal drugs regulated by EMA (European Medicines Agency), and summary of opinion published by EMA based on the CHMP's or CVMP's positive or negative recommendation.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "withdrawn" (case insensitive) to show drugs withdrawn.
Possible marketing statuses: Authorised, Refused, Withdrawn, Summary of Opinion.
Summary of Opinion: published by European Medicines Agency (EMA) based on the CHMP's or CVMP's positive or negative recommendation. Further marketing authorization is partially based on this opinion.
⬤ any of (authorization/withdrawn/opinion/status change) date within 7 days.
⬤ any of (authorization/withdrawn/opinion/status change) date within 30 days.
⬤ any of (authorization/withdrawn/opinion/status change) date within 90 days.
Category | Sponsor | Authorization Date | Current Marketing Status | Status Date | Drug Name | Active Ingredient |
---|---|---|---|---|---|---|
Human | Teva Canada Limited | 2009-07-09 | Dormant | 2024-03-19 | Act Amlodipine | Amlodipine (Amlodipine Besylate) (2.5 Mg) |
Human | Teva Canada Limited | 2001-09-10 | Dormant | 2024-02-28 | Teva Levocarbidopa | Carbidopa (10 Mg)|Levodopa (100 Mg) |
Human | Teva Canada Limited | 2023-10-11 | Marketed | 2024-02-26 | Ranopto | Ranibizumab (10 Mg) |
Human | Teva Canada Limited | 2002-11-05 | Cancelled Pre Market | 2024-02-20 | Fluvoxamine Tablets | Fluvoxamine Maleate (100 Mg) |
Human | Teva Canada Limited | 2002-11-05 | Cancelled Pre Market | 2024-02-20 | Fluvoxamine Tablets | Fluvoxamine Maleate (50 Mg) |
Human | Teva Canada Limited | 2024-02-19 | Approved | 2024-02-19 | Atorvastatin | Atorvastatin (Atorvastatin Calcium) (10 Mg) |
Human | Teva Canada Limited | 2024-02-19 | Approved | 2024-02-19 | Atorvastatin | Atorvastatin (Atorvastatin Calcium) (20 Mg) |
Human | Teva Canada Limited | 2024-02-19 | Approved | 2024-02-19 | Atorvastatin | Atorvastatin (Atorvastatin Calcium) (40 Mg) |
Human | Teva Canada Limited | 2024-02-19 | Approved | 2024-02-19 | Atorvastatin | Atorvastatin (Atorvastatin Calcium) (80 Mg) |
Human | Teva Canada Limited | 2004-07-05 | Marketed | 2024-02-16 | Teva Fluvoxamine | Fluvoxamine Maleate (50 Mg) |
Human | Teva Canada Limited | 2004-07-05 | Marketed | 2024-02-16 | Teva Fluvoxamine | Fluvoxamine Maleate (100 Mg) |
Human | Teva Canada Limited | 2003-12-09 | Marketed | 2024-02-15 | Teva Paroxetine | Paroxetine (Paroxetine Hydrochloride Acetone Solvate) (20 Mg) |
Human | Teva Canada Limited | 2003-12-09 | Marketed | 2024-02-15 | Teva Paroxetine | Paroxetine (Paroxetine Hydrochloride Acetone Solvate) (30 Mg) |
Human | Teva Canada Limited | 2003-12-09 | Marketed | 2024-02-15 | Teva Paroxetine | Paroxetine (Paroxetine Hydrochloride Acetone Solvate) (10 Mg) |
Human | Teva Canada Limited | 2024-01-02 | Marketed | 2024-01-08 | Teva Naloxone Nasal Spray | Naloxone Hydrochloride (4 Mg) |
Human | Teva Canada Limited | 2024-01-03 | Approved | 2024-01-03 | Teva Tofacitinib | Tofacitinib (Tofacitinib Citrate) (5 Mg) |
Human | Teva Canada Limited | 2024-01-03 | Approved | 2024-01-03 | Teva Tofacitinib | Tofacitinib (Tofacitinib Citrate) (10 Mg) |
Human | Teva Canada Limited | 2017-05-01 | Marketed | 2023-12-01 | Teva Olmesartan / Hctz | Olmesartan Medoxomil (20 Mg)|Hydrochlorothiazide (12.5 Mg) |
Human | Teva Canada Limited | 2015-09-18 | Cancelled Pre Market | 2023-11-16 | Qnasl | Beclomethasone Dipropionate (40 Mcg) |
Human | Teva Canada Limited | 2015-09-18 | Cancelled Pre Market | 2023-11-16 | Qnasl | Beclomethasone Dipropionate (80 Mcg) |
Human | Teva Canada Limited | 2023-11-01 | Marketed | 2023-11-01 | Teva Rivaroxaban | Rivaroxaban (10 Mg) |
Human | Teva Canada Limited | 2023-11-01 | Marketed | 2023-11-01 | Teva Rivaroxaban | Rivaroxaban (15 Mg) |
Human | Teva Canada Limited | 2023-11-01 | Marketed | 2023-11-01 | Teva Rivaroxaban | Rivaroxaban (20 Mg) |
Human | Teva Canada Limited | 2022-09-20 | Marketed | 2023-09-22 | Teva Apixaban | Apixaban (2.5 Mg) |
Human | Teva Canada Limited | 2022-09-20 | Marketed | 2023-09-22 | Teva Apixaban | Apixaban (5 Mg) |
Human | Teva Canada Limited | 2023-09-18 | Approved | 2023-09-18 | Teva Mirtazapine | Mirtazapine (15 Mg) |
Human | Teva Canada Limited | 2023-09-18 | Approved | 2023-09-18 | Teva Mirtazapine | Mirtazapine (45 Mg) |
Human | Teva Canada Limited | 2004-10-22 | Marketed | 2023-09-18 | Teva Mirtazapine | Mirtazapine (30 Mg) |
Human | Teva Canada Limited | 2023-09-11 | Marketed | 2023-09-11 | Teva Sunitinib | Sunitinib (Sunitinib Malate) (12.5 Mg) |
Human | Teva Canada Limited | 2023-09-11 | Marketed | 2023-09-11 | Teva Sunitinib | Sunitinib (Sunitinib Malate) (25 Mg) |
Human | Teva Canada Limited | 2023-09-11 | Marketed | 2023-09-11 | Teva Sunitinib | Sunitinib (Sunitinib Malate) (50 Mg) |
Human | Teva Canada Limited | 2023-01-05 | Marketed | 2023-08-31 | Teva Sitagliptin Malate | Sitagliptin (Sitagliptin Malate) (25 Mg) |
Human | Teva Canada Limited | 2023-01-05 | Marketed | 2023-08-31 | Teva Sitagliptin Malate | Sitagliptin (Sitagliptin Malate) (50 Mg) |
Human | Teva Canada Limited | 2023-01-05 | Marketed | 2023-08-31 | Teva Sitagliptin Malate | Sitagliptin (Sitagliptin Malate) (100 Mg) |
Human | Teva Canada Limited | 2013-11-25 | Cancelled Post Market | 2023-06-28 | Novo Profen | Ibuprofen (300 Mg) |
Human | Teva Canada Limited | 2004-08-24 | Marketed | 2023-06-15 | Teva Metformin | Metformin Hydrochloride (500 Mg) |
Human | Teva Canada Limited | 2004-08-24 | Marketed | 2023-06-15 | Teva Metformin | Metformin Hydrochloride (850 Mg) |
Human | Teva Canada Limited | 2022-09-22 | Cancelled Pre Market | 2023-05-24 | Teva Lenalidomide | Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (2.5 Mg) |
Human | Teva Canada Limited | 2022-09-22 | Cancelled Pre Market | 2023-05-24 | Teva Lenalidomide | Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (5 Mg) |
Human | Teva Canada Limited | 2022-09-22 | Cancelled Pre Market | 2023-05-24 | Teva Lenalidomide | Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (10 Mg) |
Human | Teva Canada Limited | 2022-09-22 | Cancelled Pre Market | 2023-05-24 | Teva Lenalidomide | Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (15 Mg) |
Human | Teva Canada Limited | 2022-09-22 | Cancelled Pre Market | 2023-05-24 | Teva Lenalidomide | Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (20 Mg) |
Human | Teva Canada Limited | 2022-09-22 | Cancelled Pre Market | 2023-05-24 | Teva Lenalidomide | Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (25 Mg) |
Human | Teva Canada Limited | 2023-05-15 | Approved | 2023-05-15 | Teva Dapagliflozin | Dapagliflozin (5 Mg) |
Human | Teva Canada Limited | 2023-05-15 | Approved | 2023-05-15 | Teva Dapagliflozin | Dapagliflozin (10 Mg) |
Human | Teva Canada Limited | 2018-08-24 | Cancelled Post Market | 2023-04-18 | Trisenox | Arsenic Trioxide (12 Mg) |
Human | Teva Canada Limited | 2008-04-11 | Marketed | 2023-03-22 | Teva Pantoprazole | Pantoprazole (Pantoprazole Sodium Sesquihydrate) (20 Mg) |
Human | Teva Canada Limited | 2008-04-11 | Marketed | 2023-03-22 | Teva Pantoprazole | Pantoprazole (Pantoprazole Sodium Sesquihydrate) (40 Mg) |
Human | Teva Canada Limited | 2010-01-20 | Cancelled Post Market | 2023-03-21 | Teva Methylphenidate Er C | Methylphenidate Hydrochloride (18 Mg) |
Human | Teva Canada Limited | 2010-01-20 | Cancelled Post Market | 2023-03-21 | Teva Methylphenidate Er C | Methylphenidate Hydrochloride (27 Mg) |
Human | Teva Canada Limited | 2010-01-20 | Cancelled Post Market | 2023-03-21 | Teva Methylphenidate Er C | Methylphenidate Hydrochloride (36 Mg) |
Note: This table contains human, animal drugs, radiopharmaceutical and disinfectant regulated by CFIA(Canadian Food Inspection Agency) and Health Canada.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "marketed" (case insensitive) to show drugs marketed.
Possible marketing statuses: Marketed, Approved, Dormant, Cancelled Pre Market, Cancelled Post Market, Cancelled (Safety Issue), Cancelled (Unreturned Annual).
⬤ any of (authorization/status change) date within 7 days.
⬤ any of (authorization/status change) date within 30 days.
⬤ any of (authorization/status change) date within 90 days.